Transferrin receptor antibodies
The invention provides further characterization of the disease and cancer-associated antigen, transferrin receptor. The invention also provides a novel family of antibodies that bind to the transferrin receptor, methods of diagnosing and treating various human cancers and diseases that express transferrin receptor.
1. An isolated cell having ATCC No. PTA-6055.
2. An antibody expressed by hybridoma ATCC No. PTA-6055.
3. An antibody comprising an antigen-binding fragment of the antibody expressed by hybridoma ATCC No. PTA-6055.
4. An isolated antibody that binds to the LUCA31 epitope on human transferrin receptor expressed on the surface of a cancer cell comprising the three complementarity determining regions from the light chain and the three complementarity determining regions from the heavy chain of antibody LUCA31 expressed by the hybridoma having ATCC No. PTA-6055.
5. The isolated antibody of claim 4 , wherein the isolated antibody is a chimeric antibody.
6. The isolated antibody of claim 4 , wherein the isolated antibody is a humanized antibody.
7. A pharmaceutical composition comprising the isolated antibody of claim 4 and a pharmaceutically acceptable carrier.
8. The pharmaceutical composition of claim 7 , wherein the composition comprises an additional therapeutic moiety.
9. A method for producing antibody LUCA31, said method comprising growing the hybridoma having ATCC No. PTA-6055 under conditions that the antibody is expressed; and harvesting the expressed antibody.
10. The isolated antibody of claim 4 , wherein the isolated antibody is a chimeric antibody comprising the heavy chain and the light chain variable region sequences from antibody LUCA31 produced by the cell line having ATCC No. PTA-6055.
11. The isolated antibody of claim 10 , wherein the chimeric antibody comprises the heavy chain constant region sequence and the light chain constant region sequence from a human antibody.
12. An isolated antibody that binds to the LUCA31 epitope on human transferrin receptor expressed on the surface of a cancer cell comprising the heavy chain variable region sequence from antibody LUCA31 produced by the cell line having ATCC No. PTA-6055.
13. An isolated antibody that binds to the LUCA31 epitope on human transferrin receptor expressed on the surface of a cancer cell comprising the light chain variable region sequence from antibody LUCA31 produced by the cell line having ATCC No. PTA-6055.
14. An antigen-binding fragment of the isolated antibody of claim 4 , wherein the antigen-binding fragment is selected from the group consisting of a Fab, a Fab′, a F(ab′)2 and a Fv; and wherein the antigen-binding fragment retains the binding specificity of antibody LUCA31 produced by the cell line having ATCC No. PTA-6055.
15. An isolated nucleic acid comprising a sequence codimg for the isolated antibody of claim 4 .
16. The nucleic acid of claim 15 , wherein the nucleic acid is operably linked to a promoter.
17. The nucleic acid of claim 16 , wherein the promoter and the nucleic acid are contained in an expression vector.
18. The nucleic acid of claim 15 , wherein the isolated antibody is a monoclonal antibody.
19. An isolated cell line transfected, transformed, or infected with a vector containing a nucleic acid of claim 15 .
20. A method of producing a substantially purified antibody, comprising the steps of:
a. growing an isolated cell line comprising the nucleic acid of claim 15 under conditions in which the antibody encoded by the nucleic acid is expressed; and b. harvesting the expressed antibody.
21. The method of claim 20 , wherein the antibody is a monoclonal antibody.